Background The candidate malaria vaccine RTS, S/AS01E has entered phase 3 trials, but
data on long-term outcomes are limited. Methods For 4 years, we followed children who had …

Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …

Background The candidate malaria vaccine RTS, S/AS01 is being evaluated in order to
inform a decision regarding its inclusion in routine vaccination schedules. Methods We …

Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …

Background The candidate malaria vaccine RTS, S/AS01 reduced episodes of both clinical
and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing …

Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of
candidate malaria vaccine RTS, S/AS01 is being conducted in seven African countries …

Background The efficacy of RTS, S/AS01 as a vaccine for malaria is being tested in a phase
3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria …

Background The RTS, S/AS malaria vaccine is being developed for delivery through the
World Health Organization's Expanded Program on Immunization (EPI). We assessed the …

Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …

Background Results from a previous phase 3 study showed efficacy of the RTS, S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4 …